India's Lupin says it sees no supply disruption at plant despite FDA observations

MUMBAI (Reuters) - Lupin Ltd, India's third-largest drugmaker, said on Tuesday it did not expect any disruption to supply from its main manufacturing plant despite what it called minor observations made by the U.S. Food and Drug Administration after an audit.